This is to meet Evidence item 9.2.3 in the NHS DSP toolkit. i.e. The person responsible for IT has reviewed the results of the latest penetration testing, with an action…
There has been a recent increase in interest in MDMA therapy as Lykos Therapeutics intends to launch MDMA as a licensed medicine towards the end of 2024. This marks a…
This document covers information needed by the NHS DSP Toolkit under Evidence item 7.1.1. Key attributes addressed include: i. What their key operational services are, ii. What technologies and services…
1. Introduction: Pharmacy Name: [Your Pharmacy Name] Date of Analysis: [Date] 2. Objectives: To assess the current knowledge and skills of pharmacy staff regarding data security and protection. To identify…
(Name and address of pharmacy) Privacy Notice We process your personal data, which includes your name, contact details, prescription medicines and data from other pharmacy and health care services we…
In 6 months (around June 2024) the FDA (US medicine regulator) will likely approve MDMA (ecstasy) as a licensed medicine in the US. This will present a pivotal moment for…
If you are a distance-selling pharmacy attached to a private high street-based, pharmacy, the GPhC may want to inspect your premises to ensure that you are not offering face-to-face NHS…
Note: As of October 2023, psilocybin remains a Class A drug in the UK. The following article provides informational content and does not endorse or encourage illegal activities. Always adhere…
As Australia continues to explore innovative treatments for treatment-resistant depression (TRD) and other mental health conditions, esketamine has emerged as a promising therapy. Delivered via nasal spray under the brand…
As of the last update of this article in October 2022, psilocybin remains a Class A drug in the UK, making it illegal to produce, supply, or possess. The following…